Publication | Closed Access

The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models

Hematological MalignancyMedicineMalignant Blood DisorderMurine ModelsMultiple MyelomaAnti-cancer AgentPharmacologyCell BiologyTumor MicroenvironmentCancer Research